EP0633943A4 - GENTHERAPY USING TARGETED VIRAL VECTORS. - Google Patents

GENTHERAPY USING TARGETED VIRAL VECTORS.

Info

Publication number
EP0633943A4
EP0633943A4 EP93908659A EP93908659A EP0633943A4 EP 0633943 A4 EP0633943 A4 EP 0633943A4 EP 93908659 A EP93908659 A EP 93908659A EP 93908659 A EP93908659 A EP 93908659A EP 0633943 A4 EP0633943 A4 EP 0633943A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
viral vectors
targeted viral
targeted
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93908659A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0633943A1 (en
Inventor
Alexander T Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0633943A1 publication Critical patent/EP0633943A1/en
Publication of EP0633943A4 publication Critical patent/EP0633943A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
EP93908659A 1992-04-03 1993-03-31 GENTHERAPY USING TARGETED VIRAL VECTORS. Withdrawn EP0633943A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86279592A 1992-04-03 1992-04-03
US862795 1992-04-03
US4074893A 1993-03-29 1993-03-29
US40748 1993-03-29
PCT/US1993/002957 WO1993020221A1 (en) 1992-04-03 1993-03-31 Gene therapy using targeted viral vectors

Publications (2)

Publication Number Publication Date
EP0633943A1 EP0633943A1 (en) 1995-01-18
EP0633943A4 true EP0633943A4 (en) 1997-05-02

Family

ID=26717389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93908659A Withdrawn EP0633943A4 (en) 1992-04-03 1993-03-31 GENTHERAPY USING TARGETED VIRAL VECTORS.

Country Status (5)

Country Link
EP (1) EP0633943A4 (es)
JP (1) JPH07505773A (es)
AU (1) AU3940293A (es)
CA (1) CA2133411A1 (es)
WO (1) WO1993020221A1 (es)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
WO1994011524A1 (en) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Targetable vector particles
DE69520496T2 (de) * 1994-05-13 2001-07-12 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
WO1997024453A1 (en) * 1995-12-28 1997-07-10 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
NZ335738A (en) 1996-11-15 2001-02-23 Canji Inc Nucleic acid encoding a fusion polypeptide which comprises a fusion of a DNA binding domain of E2F transcription factor and a functional growth suppression domain of retinoblastoma polypeptide
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
EP0973538B1 (en) 1997-04-10 2008-03-12 University of Southern California Modified proteins which bind extracellular matrix components
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
ATE525477T1 (de) 1998-03-30 2011-10-15 Northwest Biotherapeutics Inc Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
JP4227302B2 (ja) 1998-04-07 2009-02-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
DE19904800C1 (de) * 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AU5011400A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in t cells
JP2003514524A (ja) 1999-11-18 2003-04-22 コルバス・インターナショナル・インコーポレイテッド エントセリアーゼをコードしている核酸、エンドセリアーゼおよびその使用
DK1250453T3 (da) 1999-12-10 2008-08-11 Invitrogen Corp Anvendelse af multiple rekombinations-sites med unik specificitet i rekombinationskloning
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
EP1967206B1 (en) 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
TWI327599B (en) 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
JP4309758B2 (ja) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
US7449562B2 (en) 2001-06-29 2008-11-11 Novartis Ag PERV screening method and use thereof
WO2003046176A2 (en) 2001-11-26 2003-06-05 Hybrigenics Protein-protein interactions in human immunodeficiency virus
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
UA81634C2 (ru) * 2002-07-18 2008-01-25 Хеликс Биофарма Корп. Фармацевтическая композиция уреазы для ингибирования роста раковых клеток и ее применение
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1636248A4 (en) 2002-12-16 2006-09-06 Halozyme Inc HUMAN CHONDROITINASE GLYCOPROTEIN (CHASEGP), PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID GLYCOPROTEIN
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8021833B2 (en) 2003-02-12 2011-09-20 Functional Genetics, Inc. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US8183011B2 (en) 2003-06-13 2012-05-22 University Of Medicine And Dentistry Of New Jersey RNA interferases and methods of use thereof
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
WO2005014795A2 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
CA2540529C (en) 2003-10-03 2012-03-13 Vib Vzw Means and methods for the recruitment and identification of stem cells
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
JP4790619B2 (ja) 2003-10-27 2011-10-12 ロゼッタ インファーマティクス エルエルシー 遺伝子サイレンシングのためのｓｉＲＮＡを設計する方法
KR20130041373A (ko) 2003-12-23 2013-04-24 제넨테크, 인크. 신규 항-ｉｌ１３ 항체 및 그 용도
EP1786463A4 (en) 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
EP1968565B1 (en) 2004-04-16 2015-11-18 Sun Baocun Compositions and methods for inhibiting angiogenesis
EP2383350B1 (en) 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
AU2005262329A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
EP1778268B1 (en) 2004-07-21 2016-05-04 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP2008525479A (ja) 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
SI1919503T1 (sl) 2005-08-10 2015-02-27 Macrogenics, Inc. Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
EP1945816B1 (en) 2005-10-21 2011-07-27 GeneNews Inc. Method and apparatus for correlating levels of biomarker products with disease
CN101355956A (zh) 2005-11-04 2009-01-28 健泰科生物技术公司 利用补体途径抑制剂治疗眼部疾病
JP5366554B2 (ja) 2005-11-12 2013-12-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー うつを診断および処置するためのｆｇｆ２関連方法
JP5367563B2 (ja) 2006-03-30 2013-12-11 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
WO2008019199A2 (en) 2006-06-26 2008-02-14 Macrogenics, Inc. FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR101314362B1 (ko) 2006-08-28 2013-10-10 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체
AU2007324128B2 (en) 2006-10-10 2013-10-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US20100143254A1 (en) 2006-10-16 2010-06-10 Medimmune, Llc Molecules with reduced half-lives, compositions and uses thereof
AU2007323799B2 (en) 2006-11-15 2013-07-18 Eli Lilly And Company Anti-TSG101 antibodies and their uses for treatment of viral infections
CL2007003661A1 (es) 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
AU2008269689A1 (en) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
RS57273B1 (sr) 2007-08-29 2018-08-31 Sanofi Sa Humanizovana anti-cxcr5 antitela, njihovi derivati i njihove primene
ES2654937T3 (es) 2008-04-02 2018-02-15 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
BRPI0906309A2 (pt) 2008-04-02 2020-05-26 Macrogenics, Inc Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN102282172B (zh) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
KR101940059B1 (ko) 2008-12-19 2019-01-18 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
EP2367564A1 (en) 2008-12-22 2011-09-28 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
EP2424978B1 (en) 2009-04-27 2018-08-15 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
DK2437767T3 (en) 2009-06-01 2015-09-28 Medimmune Llc MOLECULES WITH EXTENDED half-lives and uses thereof
ES2553440T3 (es) 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
EP2488186B1 (en) 2009-10-16 2017-05-24 National University of Singapore Anti-neoplastic uses of artemin antagonists
WO2011054001A2 (en) 2009-11-02 2011-05-05 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2011057188A1 (en) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
DK2536747T3 (en) 2010-02-19 2017-12-04 Université de Liège POLYNUCLEOTIDE USED FOR THE TREATMENT OF INFLUENZA A VIRUS-INDUCED DISEASES AND CODING MODIFIED MX PROTEIN, THE MODIFIED MODIFIED MX PROTEIN, AND A TRANSGENT ANIMATED DRIVE, AS AN EXTENDED ANIMALS, AS AN EXTERNAL DRIVE, AS AN EXTENDED ANIMALS
AR082149A1 (es) 2010-07-09 2012-11-14 Calmune Corp Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
WO2012013249A1 (en) 2010-07-30 2012-02-02 Université de Liège Dentin matrix protein 1 (dmp1) for use in pharmaceutical compositions
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
US10130687B2 (en) 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
WO2013040309A2 (en) 2011-09-16 2013-03-21 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
US9732130B2 (en) 2011-09-16 2017-08-15 Ottawa Hospital Research Institute WNT7A compositions and method of using the same
CN108103069B (zh) 2012-02-15 2021-08-10 诺和诺德股份有限公司 结合并阻断髓样细胞表达的触发受体-1 (trem-1)的抗体
PL2814842T3 (pl) 2012-02-15 2018-12-31 Novo Nordisk A/S Przeciwciała wiążące białko 1 rozpoznające peptydoglikan
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
EP3450571B1 (en) 2014-02-24 2023-04-05 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
TN2017000008A1 (en) 2014-07-17 2018-07-04 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
CA2966634A1 (en) 2014-11-17 2016-05-26 Adicet Bio Inc. Engineered gamma delta t-cells
WO2016191418A1 (en) 2015-05-26 2016-12-01 Salk Institute For Biological Studies Motor neuron-specific expression vectors
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
WO2017182981A1 (en) 2016-04-20 2017-10-26 Washington University Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHODS FOR SELECTIVE MULTIPLICATION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
AU2018370120B2 (en) 2017-11-15 2023-11-09 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
JOP20200240A1 (ar) 2018-04-02 2020-09-27 Bristol Myers Squibb Co أجسام مضادة ضد- trem-1 واستخداماتها
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
JP2022510387A (ja) 2018-12-03 2022-01-26 アディセット バイオ， インコーポレイテッド ガンマデルタｔ細胞集団の選択的生体内増殖方法及びその組成物
CR20210669A (es) 2019-05-27 2022-05-05 Immatics Us Inc Vectores víricos y uso de los mismos en terapias celulares adoptivas
JP2023510195A (ja) 2020-01-03 2023-03-13 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるｔｎａｐ
CN115427554A (zh) 2020-02-24 2022-12-02 伊玛提克斯美国公司 扩增t细胞治疗癌症和相关恶性肿瘤的方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
CA3203118A1 (en) 2020-12-31 2022-07-07 Gagan BAJWA Cd8 polypeptides, compositions, and methods of using thereof
AU2021421391A1 (en) 2021-01-24 2023-07-20 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
IL308337A (en) 2021-05-13 2024-01-01 Us Health Preparations and methods for the treatment of sickle cell disease
CA3226402A1 (en) 2021-07-19 2023-01-26 Dounia ABBADI Adeno-associated viral vector compositions and methods of promoting muscle regeneration
WO2023064255A2 (en) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnosis and treatment of anti-pf4 induced thrombocytopenia
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023131901A1 (en) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2023200897A1 (en) 2022-04-13 2023-10-19 The Regents Of The University Of California Use of viral il-6 in cancer therapy
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
WO1992014829A1 (en) * 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env
WO1993014188A1 (en) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
WO1992014829A1 (en) * 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env
WO1993014188A1 (en) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. MARTIN ET AL.: "Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurivirulent for mice", EMBO J., vol. 7, no. 9, September 1988 (1988-09-01), OXFORD UNIVERSITY PRESS,GB;, pages 2839 - 2847, XP002025309 *
B. GOUD ET AL.: "Antibody-mediated binding of a murine ecotropic miloney retroviral vector to human cells allows internalization but not the establishment of the proviral state", VIROLOGY, vol. 163, no. 3, March 1988 (1988-03-01), ACADEMIC PRESS, INC.,NEW YORK, US, pages 251 - 254, XP000613633 *
DONG J ET AL: "A CHIMERIC AVIAN RETROVIRUS CONTAINING THE INFLUENZA VIRUS HEMAGGLUTININ GENE HAS AN EXPANDED HOST RANGE", JOURNAL OF VIROLOGY, vol. 66, no. 12, 1 December 1992 (1992-12-01), pages 7374 - 7382, XP002011560 *
HIROSHI NEDA ET AL: "CHEMICAL MODIFICATION OF AN ECOTROPIC MURINE LEUKEMIA VIRUS RESULTS IN REDIRECTION OF ITS TARGET CELL SPECIFICITY", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991 (1991-08-05), pages 14143 - 14146, XP000612122 *
S.D. LONDON ET AL.: "Infectious enveloped RNA virus antigenic chimeras", PROC. NATL.ACAD SCI., vol. 89, January 1992 (1992-01-01), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 207 - 211, XP002025310 *
See also references of WO9320221A1 *

Also Published As

Publication number Publication date
JPH07505773A (ja) 1995-06-29
WO1993020221A1 (en) 1993-10-14
CA2133411A1 (en) 1993-10-14
AU3940293A (en) 1993-11-08
EP0633943A1 (en) 1995-01-18

Similar Documents

Publication Publication Date Title
EP0633943A4 (en) GENTHERAPY USING TARGETED VIRAL VECTORS.
EP0688358A4 (en) IMPROVED VECTORS FOR GENTHERAPY
AU3972893A (en) Gene therapy using the intestine
EP0554376A4 (en) Dna construct for providing rna therapy
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
GB9524973D0 (en) Viral vectors
EP0625049A4 (en) EX VIVO GENTRANSFER.
AU2552795A (en) Safe vectors for gene therapy
EP0789592A4 (en) GENE EYE THERAPY
EP0710123A4 (en) ADENOVIRUS VECTORS FOR GENE THERAPY
AU2678097A (en) Targeted viral vectors
IL110284A0 (en) Viral vectors and their use in gene therapy
EP0666752A4 (en) THERAPEUTIC MICROEMULSIONS.
AU3434393A (en) Targeted virus
ZA945414B (en) DNA virus ribozymes
AU6014094A (en) Episomal vectors for gene therapy
AU1768192A (en) Rna delivery vector
EP0723460A4 (en) GENE THERAPY FOR THE NERVOUS SYSTEM
OA09427A (en) "Viral treatment system".
GB9306386D0 (en) Gene expression
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
GB2322131B (en) Improved retroviral vectors for gene therapy
EP0626971A4 (en) Recombinant gibberellin dna and uses thereof.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970311

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020709